For more information on our ongoing clinical trials, please click on the appropriate link
The discovery of the BRAF gene and its potential role in melanoma is an exciting breakthrough and has led to the development of a new experimental therapy PLX-4032 (zelboraf). This treatment, now FDA approved, has been shown to cause programmed death of melanoma cell lines, successfully fighting this disease in patients with aggressive skin cancer that cannot be cured by surgery.
Monoclonal antibodies against programmed death 1 protein (PD-1) and its ligand (PD1-L1) may also become important treatments for advanced melanoma in the future. Currently the use of these new drugs is restricted to patients enrolled in clinical trials.